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IN a previous paper the excretion of oestrogens, 17-oxosteroids and 17-oxogenic
steroids by men with untreated prostatic cancer was compared with that of
controls of the same age, and the effects of treatment by synthetic oestrogens
or by castration were briefly described (Bulbrook, Franks and Greenwood, 1959).
The present paper describes in detail the changes which occur within the first
two years oftreatment ofprostatic cancer by castration or by the administration
of synthetic oestrogens and attempts to correlate the clinical effects of such
treatment with the changes in hormone excretion in eight patients.
MATERIAL
Eight patients with prostatic cancer, (aged 66 to 80 years), were admitted to
hospital and 24 hour urine specimens collected for three to fifteen days before
treatment. Thepatients werere-admitted tohospital atintervals duringtreatment
for clinical evaluation and urine collections. The clinical diagnosis was confirmed
histologically in five cases and cytologically (prostatic smear) in the remaining
four. Treatment was by surgical castration (three patients) or by synthetic
oestrogens (five patients). The clinical assessment was made without knowledge
ofthe biochemical findings.
CHEMICAL METHODS
Chemical methods used are as previously described (Bulbrook, Franks and
Greenwood, 1959). The effects of synthetic oestrogen treatment on the urinary
oestrogen excretion are given for oestrone and oestriol only since the oestradiol-
17, fraction cannot be measured accurately in urine from these patients. Intra-
venous diethyl stilboestrol phosphate also interferes with the measurement of
oestrone and in one case where this compound was given only oestriol values are
reported.
RESULTS
A brief description of the clinical and biochemical findings is given for each
patient. The hormone excretion ofthe 8 patients is shown graphically in Fig. 1 to
8. Periods ofclinical tumour activity are shown by a black bar; periods ofremis-
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All periods of time have been taken from the day of operation or the start of
treatment. The mean hormone excretion in the pre-treatment period-the control
level-has been used as the baseline for comparing subsequent hormone determina-
tions during treatment. Age refers to that at operation or at the start oftreatment.
a. Castration: its effects onthe clinicalstate and on the excretionofoestrone, oestradiol-
17fl, oestriol, 17-oxosteroids and 17-oxogenic steroids. (Group of three patients)
Patient No. 1, aged 66 years, was admitted with incontinence and supra-pubic
pain. The prostate was clinically malignant and aprostatic smear contained malig-
nant cells. The serum acid phosphatase (formalin inactivated) was 3.0 units.
There were no skeletal metastases on X-ray examination. After a control period of
9 days the patient was treated by castration and per-urethral resection. The
resected tissue contained areas of anaplastic carcinoma. The changes in hormone
excretion are shown in Fig. 1. In the immediate post-operative period there was
a marked rise in excretion ofall three groups of steroids measured. This phenome-
non has been frequently observed to follow operation and is probably due to an
adrenal cortical reaction to stress. After this initial rise the amounts of excreted
oestrogens and 17-oxosteroids fell progressively to pre-operative levels. Oestrogens
were not detected in the urine 14 weeks after operation, and the 17-oxosteroid
excretion was very low. Clinically there was a marked improvement with complete
freedom from symptoms. Over the period from 33 to 65 weeks after operation,
oestrogen was again detectable in the urine increasing to pre-operative levels
and accompanied by an increase in 17-oxosteroid secretion. This period was
characterised by the appearance and subsequent development of metastases in
the pelvis and spine. When the patient complained ofpain, 72 weeks after castra-
tion, stilboestrol was given. This was followed by rapid objective and subjective
improvement and asecond fallin oestrogen and 17-oxosteroid levels. The excretion
of 17-oxogenic steroids remained unchanged throughout the period of observation.
Patient No. 2, aged 70 years, was admitted complaining of urinary difficulty
for 6 months. Clinically the prostate was malignant andprostatic smears contained
malignant cells (confirmed by later biopsy). The serum acid phosphatase was
1-5 units. There were no skeletal metastases on X-ray examination. The patient
was castrated and the post-operative hormonal changes are shown in Fig. 2.
A transient rise in oestrogen excretion in the immediate post-operative period
was followed by a fall to below the pre-operative levels. Later specimens obtained
during follow-up showed a return of excretion to pre-operative values. The 17-
oxosteroid levels showed no significant change at operation or in the following
46 weeks, whereas the 17-oxogenic steroids showed a slow fall after operation to
low levels but with one exceptionally high value. Clinically the operation resulted
in the disappearance ofurinary symptoms and an arrest in the tumour growth up
to 44 weeks. The re-appearance of mild urinary symptoms was noted some 32
weeks afterthe return ofoestrogen excretion topre-operative levels, and on exami-
nation the prostate was enlarged and hard. This patient died 78 weeks after
castration with left ventricular failure. Histologically the prostate removed at
autopsy showed many areas ofgrowing tumour.
Patient No. 3, aged 70 years, had a retropubicprostatectomy when 63 years old.
Histologically there was an area of prostatic carcinoma in the tissue removed.
No treatment was given.HORMONE EXCRETION IN PROSTATIC CANCER
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FIG. 1.-The effect ofcastration cn the excretion ofoestrogens, 17-oxosteroids and 17-oxogenic
steroids.
Patient 1, aged 66 years.
The vertical arrows show the day of treatment.
C = castration.
S = stilboestrol.
Each vertical column gives the result of a duplicate determination on a 24 hour urine
specimen. For the oestrogens, the height of the block shows the total amount excreted, sub-
divided into oestrone (U), oestradiol ([L:) and oestriol (E[).
The horizontal bar at thetop ofthe figure indicates clinical state. The black areas represent
tumour growth; the white areas represent regression. All subsequent figures are plotted in
the same way.
4748 R. D. BULBROOK L. M. FRANKS AND F. C. GREENWOOD R.D BUBROO, L M.FRANS AD r C. REEWOO
W32-
124-
410
16
o8
0
e012
10-
0
6.
0u) 4tl
0 5 10 15 20 67 136 222 325 Days
FIG. 2.-The effect of castration on the excretion of oestrogens, 17-oxo-and 17-oxogenic steroids.
Patient 2, aged 70 years.HORMONE EXCRETION IN PROSTATIC CANCER
He was admitted to hospital 7 years later with a two months' history ofpain
in the right thigh. X-rays showed osteosclerotic deposits in the pelvis, femur
and lumbar spine. The serum acidphosphatase was raised (45.8units). Castration
resulted in clinical improvement, a fall in serum acid phosphatase to 2.3 units
but no immediate reduction in urinary oestrogens, 17-oxosteroids or 17-oxogenic
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FIo. 3.-Theeffect ofcastrationontheexcretion ofoestrogens, 17-oxo- and 17-oxogenicsteroids.
Patient 3, aged 70 years.
steroids. Clinical improvement and the lowered serum acid phosphatase was
maintained up to 92 weeks after operation. During this time oestrogen excretion
fell progressively to belowpre-operative levels and at the last follow-up no urinary
oestrogen was found, whilst the 17-oxosteroids and 17-oxogenic steroids have
remained unchanged.
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b. Synthetic oestrogen: the effects of administration on clinical state and on the
excretion of oestrone, oestriol, 17-oxosteroids and 17-oxogenic steroids. (Group
offivepatients.)
Patient No. 4, aged 69 years, when first seen complained of dysuria and back-
ache,pain on micturition, suprapubic pain and left sciatic pain. The prostate was
moderately enlarged, fixed, hard and irregular. A per-urethral resection was
carried out. Histological examination showed an adenocarcinoma with moderate
fibroblastic reaction. After a 6-day control period, stilboestrol was given (50 mg.
twice daily). There was little effect on oestrogen excretion for the first 5 days but
thereafter the excretion ofoestriol fell progressively (Fig. 4). At the firstfollow-up
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FIG. 4.-The effect of synthetic oestrogen administration on the excretion of oestrogens, 17-
oxo- and 17-oxogenic steroids.
Patient 4, aged 69 years.
The dotted break in the line showing the period ofstilboestrol treatment denotes a period
when the patient stopped taking the drug.
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at 8 weeks, the amount of oestriol in the urine almost equalled the control level
but after 18 weeks of treatment oestrogen levels were considerably depressed
(30 per cent of control mean level). However, during three subsequent follow-up
periods oestrogen excretion increased, and at 68 and 102 weeks the amounts were
equivalent to the control levels. For some of this time the patient had not taken
stilboestrol regularly because of indigestion and subsequently dienoestrol was
given (10 mg. three times a day). The fall in endogenous oestrogen excretion after
treatment was paralleled by clinical improvement; the rise to control levels was
associated with a return ofurinary symptoms.
17-Oxosteroid and oxogenic steroid excretion was not altered by treatment.
The serum acid phosphatase before treatment was 2.5 units; at the last follow-
up, at 102 weeks, it was 1 1 units.
Patient No. 5, aged 78 years, complained ofsevere frequency ofmicturition and
dysuria. The prostate was small and hard and a prostatic smear contained malig-
nant cells. There were no metastasesradiologically. After an 8-day control period,
stilboestrol (50 mg. twice daily) was given. During the first few days oftreatment
both oestrogen and oxosteroid excretion rose but thereafter the amount of oestro-
gen excreted fell to a very low level, while 17-oxosteroids decreased slightly.
After 8 weeks the stilboestrol was replaced by TACE (chlorotrianisene, 12
mg. t.d.s.). At the first follow-up, 13 weeks after the start of treatment, urinary
oestrogens were still barely detectable and by this time 17-oxosteroid excretion
was also greatly depressed. At 37 weeks, oestrogen excretion had risen to control
levels and 17-oxosteroids had increased slightly. At 73 weeks, the amounts of
17-oxosteroids were approaching the mean control level. The patient's clinical
state improved on treatment and the improvement was maintained in spite of
the rise in oestrogens and 17-ketosteroids. Serum acid phosphatase levels fell
from 7.5 before treatment to 0-4 units by the last follow-up. 17-Oxogenic steroid
levels were depressed, and remained so, at all follow-up periods.
Patient No. 6, aged 72 years, had suffered from backache and pain radiating
down the left leg for 6 months. The prostate was enormous and craggy, pressing
on, but not ulcerating, the rectum. The prostatic smear was positive. The serum
acidphosphatase was 120 units; the serum alkalinephosphatase, 92 units. X-ray
examination showed metastases in the lumbar and dorsal spine, pelvis, thoracic
cage, and the upper end ofthe left femur. After a 7-day control period the patient
was treated by intravenous diethylstilboestrol phosphate for a period of 13 days
without benefit. The serum acid phosphatase at the end of this treatment was
122 units; the serum alkaline phosphatase was 82 units. Administration of
diethylstilboestrol phosphate made it impossible to measure oestrone and
oestradiol-17/ in the urine. Oestriol levels were depressed by treatment. 17-
Oxosteroid excretion did not change but the level of 17-oxogenic steroids fell to
approximately 30 per cent of control values. Diethylstilboestrol phosphate
was stopped and stilboestrol (50 mg. b.d.) started. Oestriol excretion declined
further and 17-oxosteroid excretion, unaffected by the previous treatment,
progressively fell; the 17-oxogenic steroids remained depressed. The fall in
hormone excretion was accompanied by an objective regression with decrease
of pain. The serum acid-phosphatase fell to 75 units and the serum alkaline
phosphatase fell to 43 units. Over the following 20 weeks the serum acid phos-
phatase fell progressively to 15 units, the serum alkaline phosphatase to 18 units.
X-ray examination at 18 weeks showed that the metastases were more sclerotic.
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FIG. 5.-The effect of synthetic oestrogen administration on the excretion of oestrogens,
17-oxo- and 17-oxogenic steroids.
Patient 5, aged 78 years.
At the first follow-up (21 weeks) oestrogen levels were still low but 17-oxo-
steroids and 17-oxogenic steroids were at control levels. X-ray examination
showed metastases in the right shoulder. The serum acid phosphatase was now
7.O units and the serum alkaline phosphatase 12 units.
At the last follow-up (54 weeks), oestrogen excretion had increased and, with
the 17-oxosteroids, was at control levels, but 17-oxogenic steroids were depressed.
Although the general condition was good the secondary deposits previously
noted had developed. The serum acid phosphatase was 3.2 units and the serum
alkaline phosphatase was 8.4 units.
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administration on the excretion of oestrogens,
Patient 6, aged 72 years.
S = stilboestrol.
D.S.P.= diethylstilboestrol phosphate.
Patient No. 7, aged 80 years, was first admitted with acute retention of urine.
A per-urethral biopsy showed one small nodule of prostatic carcinoma of low
grade. Serum acid phosphatase was 1.1 units. Fifteen months later there was
haematuria and the prostate (per rectum) was hard and clinically malignant.
Theurine deposit contained malignant cells. TACE (12 mg. t.d.s.) wasadministered
and over the first 10 days oftreatment no change occurred in hormone excretion.
At the first follow-up (11 weeks) the patient was well. At this stage, oestrogen
excretion had fallen to zero; 17-oxosteroid and 17-oxogenic steroid levels were
depressed. Serum acid phosphatase was 1-5 units.
At the second follow-up (34 weeks), oestrogen was again detected in the urine
but at a level well below that of the control period. 17-Oxosteroids and 17-
oxogenic steroids were lower than at the previous follow-up. The serum acid
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phosphatase was 0.8 units. The patient remained well but subsequently died of
coronary thrombosis.
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FiG. 7.-The effectofsynthetic oestrogenadministration ontheexcretion ofoestrogens, 17-oxo-
and 17-oxogenic steroids.
Patient 7, aged 80 years.
Patient No. 8, aged 80 years, was admitted to hospital with slight frequency
and pain on micturition. On examination the prostate was hard and the smear
positive. The serum acid phosphatase was 0.4 units. X-ray examination showed
osteoarthritis inthe spine but nosecondarydeposits. Stilboestrol was administered
(50 mg. b.d.) after a 6-day control period. Oestrogen excretion was very variable
but in the first 8 days treatment did not affect the mean amount excreted. 17-
Oxosteroid excretion fell slowly over the 8 days studied; 17-oxogenic steroid
excretion increased slightly.
At the first follow-up (9 weeks) oestrogen excretion was zero and remained so
at subsequent examinations. 17-Oxosteroid excretion remained depressed
throughout the 85-week period of study.
At the third follow-up (27 weeks), 17-oxogenic steroid excretion was markedly
depressed but rose topre-treatment levels at 52 weeks and remained so at 85 weeks.
The serum acidphosphatase was normal throughout and the patient has remained
in remission.HORMONE EXCRETION IN PROSTATIC CANCER
The administration of synthetic oestrogens, therefore, generally resulted in a
fall inthe excretion ofendogenous oestrogeneitherimmediately or after atransient
rise during the first few days of treatment. The fall was not permanent since in
only one case were the oestrogen levels permanently depressed.
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FIG. 8.-The effect of synthetic oestrogen administration on the excretion of oestrogens, 17-oxo- and 17-oxogenic steroids.
Patient 8, aged 80 years.
In this series synthetic oestrogens had little or no immediate effect on 17-
oxosteroid excretion. In four cases this fraction was depressed (No. 5, 6, 7 and 8),
and a minimum of7 days treatment was required for the effect to become manifest.
In the fifth case (No. 4), 17-oxosteroid excretion was unchanged over 102 weeks of
treatment. In only two of the five cases was there a return to normal levels.
With the exception of Case No. 4, 17-oxogenic steroid excretion was depressed
by treatment, the effect taking a week to become apparent. This fall was main-
tained over a long period in three patients (No. 5, 6 and 7) but in the remaining
case (No. 8), excretion had risen to the control level by 52 weeks.
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Oestrogen: androgen ratios
The pre-treatment oestrogen levels for the 8 patients described were divided
by the 17-oxosteroid levels and the ratios obtained compared with those obtained
from the data for normal controls without prostatic cancer (Bulbrook, Franks
and Greenwood, 1959). There was no significant difference between the mean
ratios for the two groups (0.0011 and 0.0019 respectively). In both groups the
daily oestrogen/17-oxosteroid ratio was fairly constant for a particular subject
but there was a 20-fold variation between individual subjects.
DISCUSSION
Changes in excretion after treatment
In a previous paper (Bulbrook, Franks and Greenwood, 1959) we have shown
that the excretion of oestrogens, 17-oxosteroids and 17-oxogenic steroids in men
with untreated prostatic cancer does not differ significantly from that found in
patients of a similar age without clinical cancer. However after treatment with
synthetic oestrogens or by castration there is a temporary fall in the excretion of
one or more of the three groups of hormones measured, followed by a rise to pre-
treatment levels. This biphasic response is shown most clearly by the oestrogens.
The time taken for these changes to occur varies from patient to patient. Clinical
improvement tends to precede marked decrease in hormone excretion, but the
period of lowest hormone excretion was generally associated with retardation of
tumourgrowth. The increase inhormoneexcretionto controllevelsagaingenerally
preceded clinical signs ofrenewed tumour growth.
When the results are considered in detail several further points arise. There is
little doubt about the biphasic response to oestrogen treatment or to castration;
the fall and subsequent rise in excretion of at least one of the three groups of
hormones is generally marked. There are two other effects which are so slight that
there must be some doubt as to their general occurrence. The first of these is the
slight and transient rise in 17-oxosteroids, 17-oxogenic steroids oroestrogenswhich
sometimes occurs in the first two or three days after treatment with synthetic
oestrogen is started. In the 17-oxosteroid fraction this occurred in one patient,
in the 17-oxogenic steroids and the oestrogens in 2 patients. The subsequent fall
in excretion was clearly manifest by about the seventh day of treatment.
The second minor effect was seen in three cases (2, 5 and 6), one a castrate,
the others treated with stilboestrol. Hormone excretion fell, rose again to pre-
treatment levels and then dropped again, over a period ofseveral months. Burt,
Finney and Scott (1957) found a similar change in 3 patients treated by castration.
It is possible that this might have been found in other cases ifspecimens had been
collected at shorter intervals oftime. These changes did not seem to be associated
with changes in the clinical state and their significance is uncertain.
The effect of castration on oestrogen excretion.-In all three cases there was a
rise in excretion in the immediate post-operative period which is thought to be
an adrenal cortical reaction to operative stress. A similar rise occurs after oophor-
ectomy in the female (Bulbrook and Greenwood, 1957). Oestrogens are thought
to be mainly produced by the testes in man but in two of the three cases (No. 1
and 3) castration had virtually no immediate effect on oestrogen excretion,
suggesting that this hormone was being produced in some other organ, presumably
the adrenal. Nevertheless, over the following three months, oestrogen excretionHORMONE EXCRETION IN PROSTATIC CANCER
slowly declined. In Case 2 however oestrogen excretion fell to roughly one-third
of the pre-operative level within 14 days and there was no evidence of a further
fall at subsequent examinations.
Variability of response to treatment.-The pre-treatment hormone levels found
in this small series differed widely from patient to patient. Oestrogen excretion
varied eight-fold between the patients, 17-oxosteroids three-fold and 17-oxogenic
steroids four-fold. Although the general pattern of response to treatment was
similar, the time taken for the changes to occur and the absolute amounts of
hormones excreted during treatment were equally varied. This may be due to
differences in response, from patient to patient, to a given dose of a synthetic
oestrogen. It is possible that the most effective dose varies as widely from patient
to patient as insulin requirements in diabetics. The variation in response to
hormones may be genetically determined. This is well known in experimental
animals and it is likely that it also occurs in man.
Not only does treatment elicit a variable response from patienttopatient but in
each, thethree groups of hormones measured also varyindependently. The oestro-
gens, 17-oxosteroids and 17-oxogenic steroids do not necessarily rise and fall
together and in some cases only one or two of the three groups ofhormones show
an effect. It is probable that relative changes in excretion in the individual
patient may be of greater significance than the absolute levels.
Hormone excretion and clinical state.-The similarity of oestrogen: androgen
ratio in patients with and without clinical cancer suggests that a disturbance
of the endogenous production of these hormones is not associated with the
development of clinical prostatic cancer. However, there seems to be a rough
correlation in this group of patients between the period of clinical improve-
ment and lowered hormone excretion after treatment, particularly as far as the
urinary oestrogens are concerned. This association may be fortuitous and was not
invariably found in another series of cases which had been treated with synthetic
oestrogens for more than five years (Bulbrook, Franks and Greenwood, 1959).
All the hormones measured in this study are produced in response to stimulation
by trophic pituitary hormones. If the primary endocrine disturbance associated
with the growth of prostatic tumours is hypophyseal, the changes observed in
steroid hormone excretion may not reflect the pituitary changes very accurately.
Another possibility which must be considered is that there is a level, perhaps
varying from patient to patient, above which tumour growth is maximally stimu-
lated. In this case the absolute amount of hormones produced would not neces-
sarily be directly proportional to the growth activity.
Possible sources of error
In any clinical investigation a number of possible sources of error must be
recognised. These include amongst others the accuracy of the original diagnosis,
inadequate sample size and conscious or unconscious selection of cases. In this
investigation the clinical diagnosis has been confirmed microscopically in all cases
but it must be realised that the microscopy gives no guide to the biological
malignancy of the tumours (Franks, Fergusson and Murnaghan, 1958). In addi-
tion only a small number of patients has been studied but the findings are in
general agreement with similar investigations. In this group there has been some
selection of patients, in that the severely ill patient, with urinary obstruction
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or gross infection was unsuitable for investigation. Similarly, patients with small
"early "tumours were often treated as out-patients and not admitted to hospital.
The patients in this short-term group are therefore those with moderately severe
disease but without gross urinary disturbance.
Summary and conclu8ions
The urinary excretion of oestrogens, 17-oxosteroids and 17-oxogenic steroids
was measured in 8 patients with prostatic cancer, before and at intervals during
treatment by castration (3 cases) or synthetic oestrogens (5 cases). The excretion
ofthese hormones is depressed by such treatment but in most cases there is a later
rise to pretreatment levels. This biphasic response is shown most clearly by the
oestrogens. Objective regression oftumourgrowthinthese cases, isassociated with
depression of hormone excretion. The later rise in excretion is generally followed
by renewed tumour growth.
There is a wide variation in the response to treatment from patient to patient
and each ofthe three groups ofhormones measured may vary independently.
The changes measured may reflect changes in pituitary function. This may
be the basic endocrine factor.involved.
Our thanks are due to many people without whose help this investigation
could not have been completed and in particular to Mr. J. D. Fergusson, Institute
of Urology, St. Philip's and St. Paul's Hospitals, under whose care many of these
patients were admitted; Mr. D. Wallace, St. Peter's Hospital and Mr. G. F.
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